Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC Article
Full Text via DOI: 10.1016/j.annonc.2021.10.159
Web of Science: 000731051400143
Industry Collaboration
International Collaboration